Advertisement

Treatments in Endocrinology

, Volume 4, Issue 3, pp 131–138 | Cite as

Inhaled Insulins

Their Potential in the Treatment of Diabetes Mellitus
  • Igor Alexander Harsch
Leading Article

Abstract

The inhalation of insulin was conceptualized by the mid-1920s, but the first successful testing of inhaled insulin occurred in the mid-1990s. The lung has proven to be an organ well capable of absorbing insulin in a reproducible and dose-dependent manner. At present, two concepts of pulmonary insulin delivery at relatively advanced stages of development have been investigated in several published studies. The first involves the Exubera® device, a system consisting of a formulation of insulin in a dry and amorphous powder, which is then packaged into blisters. A special delivery system generates a pulse of compressed air, which causes the insulin to form a white fog in a transparent reservoir that can be inhaled by deep breathing. The second approach is the AERx® insulin Diabetes Management System, which uses an aqueous formulation of insulin, delivered as an aerosol generated by a special, microprocessor-controlled, inhalation device. This device is capable of monitoring the patient’s inspiratory flow and guiding the inhalation by a microelectronic feedback system. The therapeutic efficacy and safety of these inhaled insulins seem comparable to those of subcutaneous insulin regimens; however, inhaled insulins do not appear to achieve significantly better glycemic control. Several other concepts for the pulmonary delivery of insulin are also being developed.

With the incidence of diabetes mellitus, especially type 2 diabetes, dramatically increasing worldwide, patients with type 2 diabetes appear to be an important target group for new modalities of insulin delivery. In this group, the onset of insulin treatment is frequently delayed due to the fear of self-injection, preventing effective glycemic control. Patient acceptance of inhaled insulins is excellent and no serious adverse effects have been observed to date. Further advantages of inhaled insulins are the more rapid onset of insulin action and a mitigation of postprandial glucose excursions. However, there are some open questions. The most important concerns the possible long-term effects of insulin inhalation on the lung, as insulin is known to have growth-promoting properties. Thus far, there are no observations of the effects of inhaled insulin on lung structure and function that extend beyond 10 years. In patients with pulmonary disease, the smaller cumulative alveolar surface may cause problems in absorption, and in smokers the action of inhaled insulin has been shown to be stronger and with a faster onset. Furthermore, treatment with inhaled insulin requires larger doses of insulin compared with the subcutaneous route of insulin administration to achieve the same systemic effect, and the costs of this therapy could therefore be significantly higher than the costs of present insulin therapies.

Keywords

Glycemic Control Regular Insulin Alveolar Surface Pulmonary Delivery Insulin Formulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Gänsslein M. Über Inhalation von Insulin. Klin Wochenschr 1925; 4: 71CrossRefGoogle Scholar
  2. 2.
    Heubner W, deJongh SE, Laquer E. Über Inhalation von Insulin. Klin Wochenschr 1924; 3: 2342–3CrossRefGoogle Scholar
  3. 3.
    Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000; 23: 754–8PubMedCrossRefGoogle Scholar
  4. 4.
    Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002 Sep; 26Suppl. 3: S18–24PubMedCrossRefGoogle Scholar
  5. 5.
    Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357: 331–5PubMedCrossRefGoogle Scholar
  6. 6.
    Capelleri JC, Gerber RA, Kourides IA, et al. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. Diabetes Care 2000; 23: 1799–803CrossRefGoogle Scholar
  7. 7.
    Skyler JS, for the Exubera® Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera®) compared to subcutaneous insulin therapy in an intensive insulin regimen in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial [abstract]. Diabetes 2002; 51Suppl. 2: A134Google Scholar
  8. 8.
    Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001; 134: 203–7PubMedGoogle Scholar
  9. 9.
    Weiss SR, Cheng SL, Kourides IA, et al. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 2003; 163: 2277–82PubMedCrossRefGoogle Scholar
  10. 10.
    The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999; 354: 617–21CrossRefGoogle Scholar
  11. 11.
    DeFronzo R, for the Exubera® Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera®) compared with rosiglitazone in type 2 diabetes patients not optimally controlled on diet and exercise: results of a 3-month, randomized, comparative trial [abstract]. Diabetes 2003; 52Suppl. 1: A38Google Scholar
  12. 12.
    Cappelleri JC, Cefalu WT, Rosenstock J, et al. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002; 24: 552–64PubMedCrossRefGoogle Scholar
  13. 13.
    Gerber RA, Cappelleri JC, Kourides IA, et al. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001; 24: 1556–9PubMedCrossRefGoogle Scholar
  14. 14.
    Skyler J, for the Exubera® Phase II Study Group. Sustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapy [poster no. 486-P]. Diabetes 2004; 53Suppl. 2: A115Google Scholar
  15. 15.
    An B, Reinhardt R. Breath holding is not required for pulmonary administration of insulin by the AERx™ insulin diabetes management system [abstract]. Diabetes 2002; 51Suppl. 2: A127Google Scholar
  16. 16.
    Insulin inhalation. Drugs RD 2004; 5: 46–9CrossRefGoogle Scholar
  17. 17.
    Brunner GA, Baient B, Ellmerer M, et al. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001; 44: 305–8PubMedCrossRefGoogle Scholar
  18. 18.
    Hermansen K, Ronnemaa T, Petersen AH, et al. Intensive therapy with inhaled insulin via the AERx™ insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004; 27: 162–7PubMedCrossRefGoogle Scholar
  19. 19.
    Cramer J, Okikawa J, Clauson P. Compliance with inhaled insulin treatment using AERx™ iDMS [abstract]. Diabetes 2003; 52Suppl. 1: A103Google Scholar
  20. 20.
    Henry RR, Mudaliar S, Chu N, et al. Young and elderly type 2 diabetic patients inhaling insulin with the AERx™ insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol 2003; 43: 1228–34PubMedCrossRefGoogle Scholar
  21. 21.
    Henry RR, Mudaliar SR, Howland III WC, et al. Inhaled insulin using the AERx™ insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care 2003; 26: 764–9PubMedCrossRefGoogle Scholar
  22. 22.
    Himmelmann A, Jendle J, Meilen A, et al. The impact of smoking on inhaled insulin. Diabetes Care 2003; 26: 677–82PubMedCrossRefGoogle Scholar
  23. 23.
    Cappelleri JC, Gerber RA, Bell-Farrow AD, et al. Improved patient satisfaction with inhaled insulin in subjects with type 2 diabetes mellitus: results from a multicenter randomized trial [abstract]. Diabetes 2000; 49Suppl. 1: A100Google Scholar
  24. 24.
    Gerber R, Cappelleri JC, Bell-Farrow AD, et al. Improved patient satisfaction with inhaled insulin in subjects with type 1 diabetes mellitus after one year: results from a multicenter extension trial [abstract]. Diabetes 2000; 49Suppl. 1: A100Google Scholar
  25. 25.
    Heise T, Rave K, Bott S, et al. Time-action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin [abstract]. Diabetes 2000; 39Suppl. 1: A10Google Scholar
  26. 26.
    Farr SJ, McElduff A, Mather LE, et al. Pulmonary insulin administration using the AERx™ system: physiological and biochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther 2000; 2: 185–97PubMedCrossRefGoogle Scholar
  27. 27.
    McElduff A, Clauson P, Uy C, et al. Pulmonary absorption profiles of insulin during and after an upper respiratory tract infection in healthy volunteers using the AERx™ insulin diabetes management system: an open labeled cross-over study in healthy volunteers [abstract]. Diabetes 2002; 51Suppl. 2: A107Google Scholar
  28. 28.
    Sha S, Becker RHA, Willavaise SA. The effect of smoking cessation on the absorption of inhaled insulin (Exubera®) [abstract]. Diabetes 2002; 51Suppl. 1: A538Google Scholar
  29. 29.
    Gale EAM. Two cheers for inhaled insulin. Lancet 2001; 357: 324–5PubMedCrossRefGoogle Scholar
  30. 30.
    Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med 2003; 20: 886–98PubMedCrossRefGoogle Scholar
  31. 31.
    Nathan DM. Inhaled insulin for type 2 diabetes: solution or distraction? Ann Intern Med 2001; 134: 242–5PubMedGoogle Scholar
  32. 32.
    Fineberg SE, Schatz D, Krasner A, et al. Insulin antibody binding in clinical studies of inhaled insulin (Exubera®) in patients with type 1 or type 2 diabetes [poster]. American Association of Clinical Endocrinologists’ 12th annual meeting and Clinical Congress; 2003 May 14; San DiegoGoogle Scholar
  33. 33.
    Patton JS, Platz RM. Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev 1992; 8: 179–96CrossRefGoogle Scholar
  34. 34.
    Kjellstrom T, Malmquist J. Insulin effects on collagen and protein production in cultured human skin fibroblasts from diabetic and non-diabetic subjects. Horm Metab Res 1984; 16: 168–73PubMedCrossRefGoogle Scholar
  35. 35.
    Rom WN, Basset P, Fells GA, et al. Alveolar macrophages release an insulin-like growth factor I-type molecule. J Clin Invest 1988; 82: 1685–93PubMedCrossRefGoogle Scholar
  36. 36.
    Bittermann PB, Rennard RI, Hunninghake GW, et al. Human alveolar macrophage growth factor for fibroblasts. J Clin Invest 1982; 70: 808–22CrossRefGoogle Scholar
  37. 37.
    Goldstein RH, Polkis CF, Pilch PF, et al. Stimulation of collagen formation by insulin and insulin-like growth factor I in cultures of human lung fibroblasts. Endocrinology 1989; 124: 964–70PubMedCrossRefGoogle Scholar
  38. 38.
    Valente AXCN, Langer R, Stone HA, et al. Recent advances in the development of an inhaled insulin product. BioDrugs 2003;17: 9–17PubMedCrossRefGoogle Scholar
  39. 39.
    King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025. Diabetes Care 1998; 21: 1414–31PubMedCrossRefGoogle Scholar
  40. 40.
    Pfützner A, Sommerer K, Meyer T, et al. Lung distribution of radiolabeled Technosphere™/insulin [abstract]. Diabetes 2003; 52Suppl. 2: A107Google Scholar
  41. 41.
    Steiner S, Pfützner A, Wilson BR, et al. Technosphere™/insulin: proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002; 110: 17–21PubMedCrossRefGoogle Scholar
  42. 42.
    Pfützner A, Mann AE, Steiner SS. Technosphere™/insulin: a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002; 4: 589–94PubMedCrossRefGoogle Scholar
  43. 43.
    Pfützner A, Rave K, Heise T, et al. Inhaled Technosphere™/insulin results in low variability in metabolic action in type 2 diabetic patients [abstract]. Exp Clin Endocrinol Diabetes 2000; 5Suppl. 1: A113Google Scholar
  44. 44.
    Pfützner A, Pohlmann T, Hoberg C, et al. Variability of insulin absorption after subcutaneous and pulmonary application in patients with type 2 diabetes [abstract]. Diabetes 2002; 51Suppl. 2: A47Google Scholar
  45. 45.
    Fishman RS, Guinta D, Chambers F, et al. Insulin administration via the Aerodose™ inhaler: comparison to subcutaneously injected insulin [abstract]. Diabetes 2000; 49Suppl. 1: A9Google Scholar
  46. 46.
    Kim D, Mudaliar S, Chinnapongse S, et al. Dose-response relationships of inhaled insulin delivered via the Aerodose™ insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care 2003; 26: 2842–7PubMedCrossRefGoogle Scholar
  47. 47.
    Perera AD, Kapitza C, Nosek L, et al. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose™ insulin inhaler in patients with type 2 diabetes. Diabetes Care 2002; 25: 2276–81PubMedCrossRefGoogle Scholar
  48. 48.
    Edwards DA, Ben-Jeriba A, Eskew ML, et al. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998; 85: 379–85PubMedGoogle Scholar
  49. 49.
    Hrkach J, Batycky R, Chen D, et al. AIR® insulin: complete diabetes therapy via inhalation of fast-acting and slow-acting dry powder aerosols [abstract]. Diabetes 2000; 49Suppl. 1: A9Google Scholar
  50. 50.
    Pna A, Chan C, Loh MT, et al. Effects of smoking (immediate and delayed), abstinence, nicotine replacement therapy and smoking resumption on pulmonary insulin pharmacokinetics and glucodynamics [poster no. 476-P]. Diabetes 2004; 53Suppl. 2: A113Google Scholar
  51. 51.
    Kwon J-H, Lee B-H, Lee J-J, et al. Insulin microcrystal for pulmonary drug delivery [abstract]. Diabetes 2002; 51Suppl. 2: A105Google Scholar
  52. 52.
    Leach C, Kuo M-C, Perkins K, et al. Dry powder formulation of inhaled PEG-insulin yields prolonged systemic activity in dogs [abstract]. Diabetes 2003; 52Suppl. 1: A105Google Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Medical Department of the Friedrich-Alexander University Erlangen-NurembergDivision of Endocrinology and MetabolismErlangenGermany

Personalised recommendations